Edward P. Harvey

The paper uses AlphaFold-Multimer to predict nanobody binders to MRGPRX2, demonstrating in silico antibody discovery for a GPCR target.

This paper uses machine learning to predict high-affinity nanobody binders from sparse sequencing data, outperforming deep learning and semi-supervised methods with linear models.

This paper introduces GTACs, bispecific antibodies that selectively downregulate GPCRs via endocytosis and lysosomal degradation, showing high potency and selectivity for therapeutic targets.

This paper introduces a method to assess E3 ligase activity against neo-substrates using electrophilic probes, demonstrating its effectiveness with VHL and SPSB2.